Statements (55)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:drug
|
gptkbp:bfsLayer |
4
|
gptkbp:bfsParent |
gptkb:cytomegalovirus
|
gptkbp:activities |
inhibits viral DNA polymerase
|
gptkbp:appointed_by |
intravenous injection
|
gptkbp:approves |
gptkb:1996
gptkb:FDA |
gptkbp:availability |
prescription only
|
gptkbp:brand |
Vistide
|
gptkbp:class |
nucleotide analog
|
gptkbp:clinical_trial |
in immunocompromised patients
ongoing studies for other viral infections |
gptkbp:composed_of |
chemical synthesis process
|
gptkbp:contraindication |
renal impairment
hypersensitivity to cidofovir |
gptkbp:developed_by |
gptkb:Gilead_Sciences
|
gptkbp:discontinued |
in patients with severe renal impairment
|
gptkbp:dosage_form |
once a week
|
gptkbp:duration |
depends on clinical response
|
gptkbp:formulation |
sterile solution
|
https://www.w3.org/2000/01/rdf-schema#label |
cidofovir
|
gptkbp:indication |
AIDS-related CMV retinitis
|
gptkbp:ingredients |
C12 H15 Cl N2 O4 P
|
gptkbp:interacts_with |
with other nephrotoxic drugs
with probenecid |
gptkbp:invention |
held by Gilead Sciences
|
gptkbp:is_monitored_by |
renal function
|
gptkbp:is_used_for |
treating cytomegalovirus (CMV) retinitis
|
gptkbp:manager |
intravenous
|
gptkbp:marketed_as |
gptkb:Europe
gptkb:United_States |
gptkbp:pharmacokinetics |
inhibits viral replication
long half-life |
gptkbp:research |
effective against other herpesviruses
investigated for HPV treatment investigated for adenovirus infections potential use in Ebola virus treatment potential use in other viral diseases potential use in smallpox treatment studied for BK virus nephropathy studied for Zika virus treatment |
gptkbp:research_areas |
viral infections
|
gptkbp:rounds |
renal excretion
|
gptkbp:safety_features |
requires monitoring
|
gptkbp:side_effect |
gptkb:fandom
headache nausea diarrhea thrombocytopenia nephrotoxicity neutropenia ocular inflammation |
gptkbp:storage |
room temperature
|
gptkbp:treatment |
with other antiviral agents
|
gptkbp:type_of |
113852-37-2
|